Actively Recruiting
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Led by Zhongda Hospital · Updated on 2024-11-01
444
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatocellular carcinoma (HCC) patients with Vp4 \[main trunk\] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits. We aimed to assess the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with immune checkpoint inhibitors (ICIs) plus molecular targeted therapy (MTT) after irradiation stent placement (ISP) as first line treatment for HCC patients with Vp4 PVTT.
CONDITIONS
Official Title
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of hepatocellular carcinoma confirmed by tissue or clinical features
- Portal vein tumor thrombosis extending to the main portal vein (Vp4) confirmed by histology or imaging
- At least one measurable liver lesion as per RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Receiving first-line treatment with either ICIs plus molecular targeted therapy or with irradiation stent placement plus TACE within eight weeks
You will not qualify if you...
- Presence of cancer spread outside the liver (extrahepatic metastases)
- History of or current other cancers
- Prior systemic or local treatments including surgery, radiation, hepatic arterial embolization, TACE, hepatic arterial infusion, radiofrequency ablation, ethanol injection, or cryoablation within 3 months before stent placement
- Severe liver dysfunction (Child-Pugh grade C), ascites score of 3, or overt hepatic encephalopathy
- Missing important outcome data or baseline information needed for analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongda Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
Research Team
J
Jian Lu, M.D.
CONTACT
G
Gaojun Teng, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here